Anales del Sistema Sanitario de Navarra This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Treatment and cost relationship on visual acuity improvement in age-associated macular degeneration
CONCLUSION: AntiVEGF treatments (ranibizumab, aflibercept and both) maintained VA in patients with exudative AMD. In general, care and treatment costs were lower in the group that received both drugs.PMID:38009288 | DOI:10.23938/ASSN.1052 (Source: Anales del Sistema Sanitario de Navarra)
Source: Anales del Sistema Sanitario de Navarra - November 27, 2023 Category: General Medicine Authors: Josep-Oriol Casanovas-Marsal Elisa Vilad és Palomar Francisco de As ís Bartol-Puyal Rub én Hernández Vian Luis E Pablo J úlvez Source Type: research

Treatment and cost relationship on visual acuity improvement in age-associated macular degeneration
CONCLUSION: AntiVEGF treatments (ranibizumab, aflibercept and both) maintained VA in patients with exudative AMD. In general, care and treatment costs were lower in the group that received both drugs.PMID:38009288 | DOI:10.23938/ASSN.1052 (Source: Anales del Sistema Sanitario de Navarra)
Source: Anales del Sistema Sanitario de Navarra - November 27, 2023 Category: General Medicine Authors: Josep-Oriol Casanovas-Marsal Elisa Vilad és Palomar Francisco de As ís Bartol-Puyal Rub én Hernández Vian Luis E Pablo J úlvez Source Type: research

Treatment and cost relationship on visual acuity improvement in age-associated macular degeneration
CONCLUSION: AntiVEGF treatments (ranibizumab, aflibercept and both) maintained VA in patients with exudative AMD. In general, care and treatment costs were lower in the group that received both drugs.PMID:38009288 | DOI:10.23938/ASSN.1052 (Source: Anales del Sistema Sanitario de Navarra)
Source: Anales del Sistema Sanitario de Navarra - November 27, 2023 Category: General Medicine Authors: Josep-Oriol Casanovas-Marsal Elisa Vilad és Palomar Francisco de As ís Bartol-Puyal Rub én Hernández Vian Luis E Pablo J úlvez Source Type: research

Treatment and cost relationship on visual acuity improvement in age-associated macular degeneration
CONCLUSION: AntiVEGF treatments (ranibizumab, aflibercept and both) maintained VA in patients with exudative AMD. In general, care and treatment costs were lower in the group that received both drugs.PMID:38009288 | DOI:10.23938/ASSN.1052 (Source: Anales del Sistema Sanitario de Navarra)
Source: Anales del Sistema Sanitario de Navarra - November 27, 2023 Category: General Medicine Authors: Josep-Oriol Casanovas-Marsal Elisa Vilad és Palomar Francisco de As ís Bartol-Puyal Rub én Hernández Vian Luis E Pablo J úlvez Source Type: research

Treatment and cost relationship on visual acuity improvement in age-associated macular degeneration
CONCLUSION: AntiVEGF treatments (ranibizumab, aflibercept and both) maintained VA in patients with exudative AMD. In general, care and treatment costs were lower in the group that received both drugs.PMID:38009288 | DOI:10.23938/ASSN.1052 (Source: Anales del Sistema Sanitario de Navarra)
Source: Anales del Sistema Sanitario de Navarra - November 27, 2023 Category: General Medicine Authors: Josep-Oriol Casanovas-Marsal Elisa Vilad és Palomar Francisco de As ís Bartol-Puyal Rub én Hernández Vian Luis E Pablo J úlvez Source Type: research

Treatment and cost relationship on visual acuity improvement in age-associated macular degeneration
CONCLUSION: AntiVEGF treatments (ranibizumab, aflibercept and both) maintained VA in patients with exudative AMD. In general, care and treatment costs were lower in the group that received both drugs.PMID:38009288 | DOI:10.23938/ASSN.1052 (Source: Anales del Sistema Sanitario de Navarra)
Source: Anales del Sistema Sanitario de Navarra - November 27, 2023 Category: General Medicine Authors: Josep-Oriol Casanovas-Marsal Elisa Vilad és Palomar Francisco de As ís Bartol-Puyal Rub én Hernández Vian Luis E Pablo J úlvez Source Type: research

Treatment and cost relationship on visual acuity improvement in age-associated macular degeneration
CONCLUSION: AntiVEGF treatments (ranibizumab, aflibercept and both) maintained VA in patients with exudative AMD. In general, care and treatment costs were lower in the group that received both drugs.PMID:38009288 | DOI:10.23938/ASSN.1052 (Source: Anales del Sistema Sanitario de Navarra)
Source: Anales del Sistema Sanitario de Navarra - November 27, 2023 Category: General Medicine Authors: Josep-Oriol Casanovas-Marsal Elisa Vilad és Palomar Francisco de As ís Bartol-Puyal Rub én Hernández Vian Luis E Pablo J úlvez Source Type: research

Treatment and cost relationship on visual acuity improvement in age-associated macular degeneration
CONCLUSION: AntiVEGF treatments (ranibizumab, aflibercept and both) maintained VA in patients with exudative AMD. In general, care and treatment costs were lower in the group that received both drugs.PMID:38009288 | DOI:10.23938/ASSN.1052 (Source: Anales del Sistema Sanitario de Navarra)
Source: Anales del Sistema Sanitario de Navarra - November 27, 2023 Category: General Medicine Authors: Josep-Oriol Casanovas-Marsal Elisa Vilad és Palomar Francisco de As ís Bartol-Puyal Rub én Hernández Vian Luis E Pablo J úlvez Source Type: research

Treatment and cost relationship on visual acuity improvement in age-associated macular degeneration
CONCLUSION: AntiVEGF treatments (ranibizumab, aflibercept and both) maintained VA in patients with exudative AMD. In general, care and treatment costs were lower in the group that received both drugs.PMID:38009288 | DOI:10.23938/ASSN.1052 (Source: Anales del Sistema Sanitario de Navarra)
Source: Anales del Sistema Sanitario de Navarra - November 27, 2023 Category: General Medicine Authors: Josep-Oriol Casanovas-Marsal Elisa Vilad és Palomar Francisco de As ís Bartol-Puyal Rub én Hernández Vian Luis E Pablo J úlvez Source Type: research

Treatment and cost relationship on visual acuity improvement in age-associated macular degeneration
CONCLUSION: AntiVEGF treatments (ranibizumab, aflibercept and both) maintained VA in patients with exudative AMD. In general, care and treatment costs were lower in the group that received both drugs.PMID:38009288 | DOI:10.23938/ASSN.1052 (Source: Anales del Sistema Sanitario de Navarra)
Source: Anales del Sistema Sanitario de Navarra - November 27, 2023 Category: General Medicine Authors: Josep-Oriol Casanovas-Marsal Elisa Vilad és Palomar Francisco de As ís Bartol-Puyal Rub én Hernández Vian Luis E Pablo J úlvez Source Type: research

Treatment and cost relationship on visual acuity improvement in age-associated macular degeneration
CONCLUSION: AntiVEGF treatments (ranibizumab, aflibercept and both) maintained VA in patients with exudative AMD. In general, care and treatment costs were lower in the group that received both drugs.PMID:38009288 | DOI:10.23938/ASSN.1052 (Source: Anales del Sistema Sanitario de Navarra)
Source: Anales del Sistema Sanitario de Navarra - November 27, 2023 Category: General Medicine Authors: Josep-Oriol Casanovas-Marsal Elisa Vilad és Palomar Francisco de As ís Bartol-Puyal Rub én Hernández Vian Luis E Pablo J úlvez Source Type: research

Treatment and cost relationship on visual acuity improvement in age-associated macular degeneration
CONCLUSION: AntiVEGF treatments (ranibizumab, aflibercept and both) maintained VA in patients with exudative AMD. In general, care and treatment costs were lower in the group that received both drugs.PMID:38009288 | DOI:10.23938/ASSN.1052 (Source: Anales del Sistema Sanitario de Navarra)
Source: Anales del Sistema Sanitario de Navarra - November 27, 2023 Category: General Medicine Authors: Josep-Oriol Casanovas-Marsal Elisa Vilad és Palomar Francisco de As ís Bartol-Puyal Rub én Hernández Vian Luis E Pablo J úlvez Source Type: research

Treatment and cost relationship on visual acuity improvement in age-associated macular degeneration
CONCLUSION: AntiVEGF treatments (ranibizumab, aflibercept and both) maintained VA in patients with exudative AMD. In general, care and treatment costs were lower in the group that received both drugs.PMID:38009288 | DOI:10.23938/ASSN.1052 (Source: Anales del Sistema Sanitario de Navarra)
Source: Anales del Sistema Sanitario de Navarra - November 27, 2023 Category: General Medicine Authors: Josep-Oriol Casanovas-Marsal Elisa Vilad és Palomar Francisco de As ís Bartol-Puyal Rub én Hernández Vian Luis E Pablo J úlvez Source Type: research

Treatment and cost relationship on visual acuity improvement in age-associated macular degeneration
CONCLUSION: AntiVEGF treatments (ranibizumab, aflibercept and both) maintained VA in patients with exudative AMD. In general, care and treatment costs were lower in the group that received both drugs.PMID:38009288 | DOI:10.23938/ASSN.1052 (Source: Anales del Sistema Sanitario de Navarra)
Source: Anales del Sistema Sanitario de Navarra - November 27, 2023 Category: General Medicine Authors: Josep-Oriol Casanovas-Marsal Elisa Vilad és Palomar Francisco de As ís Bartol-Puyal Rub én Hernández Vian Luis E Pablo J úlvez Source Type: research

Efficacy of a cardiac rehabilitation program in a municipal sports center compared to the hospital program: randomized controlled trial eCARCEX
CONCLUSIONS: We are unable to determine the effectiveness of the out-of-hospital cardiac rehabilitation program due to a lack of power (high number of withdrawals caused by COVID-19 lockdown). However, the experimented group achieved higher HDL-cholesterol levels, while cardiac frequency in VT2 was higher in the control group.PMID:37997791 | DOI:10.23938/ASSN.1050 (Source: Anales del Sistema Sanitario de Navarra)
Source: Anales del Sistema Sanitario de Navarra - November 24, 2023 Category: General Medicine Authors: Juan Izquierdo-Garc ía Adri án Arranz-Escudero Roc ío Tello de Meneses Noelia De la Torre Isabel M Amat-Mac ías Juan I Castillo Mart ín M Paz Sanz-Ay án Guillermo Moreno Source Type: research